Skip to product information
1 of 1

FITC Rat Anti-Mouse CD39 Antibody (S-R641)

FITC Rat Anti-Mouse CD39 Antibody (S-R641)

Catalog Number: S0B5399 Application: FCM Reactivity: Ms Conjugation: FITC Brand: Starter
Price:
Regular price $200.00 USD
Regular price Sale price $200.00 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rat
Antigen CD39
Synonyms Ectonucleoside triphosphate diphosphohydrolase 1; NTPDase 1; ATP diphosphohydrolase (ATP-DPH; ATPDase); Ecto-ATP diphosphohydrolase 1 (Ecto-ATPDase 1; Ecto-ATPase 1); Ecto-apyrase; Lymphoid cell activation antigen; Nucleoside triphosphate diphosphohydrolase 1 (NTPDase1); Entpd1
Location Membrane
Accession P55772
Clone Number S-R641
Antibody Type Rat mAb
Isotype IgG2a,k
Application FCM
Reactivity Ms
Purification Protein G
Conjugation FITC
Physical Appearance Liquid
Storage Buffer

PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300

Stability & Storage 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 5 μl per million cells in 100μl volume

Background

CD39, also known as ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), is a membrane-bound enzyme that hydrolyzes extracellular nucleotides such as ATP and ADP into AMP in a Ca²⁺- and Mg²⁺-dependent manner. It plays a crucial role in regulating immune responses and vascular function. In the tumor microenvironment, CD39 works with CD73 to convert ATP into adenosine, an immunosuppressive molecule that inhibits the activity of effector immune cells while promoting the function of regulatory immune cells, thus contributing to tumor immune evasion. This protein is highly expressed in various cell types within the tumor microenvironment, including tumor cells, stromal cells, endothelial cells, and immune cells. CD39 is also involved in thromboregulation and has been identified as a potential therapeutic target for cancer immunotherapy.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)